Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 19/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.79 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12377392 | 0.91 | REN (0.65) | RENCYP3A4 | |
| SCHEMBL3343866 | 0.88 | REN (0.61) | RENCYP3A4KCNH2 | |
| SCHEMBL664854 | 0.87 | REN (0.97) | RENCYP3A4 | |
| SCHEMBL2281396 | 0.86 | REN (0.69) | RENCYP3A4KCNH2 | |
| SCHEMBL661657 | 0.86 | REN (0.79) | RENCYP3A4 | |
| SCHEMBL2290477 | 0.86 | REN (0.69) | RENCYP3A4KCNH2 | |
| SCHEMBL662677 | 0.85 | REN (1.00) | RENCYP3A4 | |
| SCHEMBL664853 | 0.84 | REN (0.86) | RENCYP3A4 | |
| SCHEMBL2288095 | 0.84 | REN (0.64) | RENCYP3A4KCNH2 | |
| SCHEMBL8083766 | 0.83 | REN (0.63) | RENCYP3A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207783-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2011-08-25 | — | — | US | disclosed |
| US-20110207783-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2011-08-25 | — | — | US | disclosed |
| US-20110207783-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2011-08-25 | — | — | US | disclosed |
| EP-2188256-A1 | RENIN INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009018662-A9 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2010-04-08 | — | — | WO | disclosed |
| WO-2009018662-A9 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2010-04-08 | — | — | WO | disclosed |
| WO-2009018662-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2009-02-12 | — | — | WO | disclosed |
| WO-2009018662-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2009-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207783-A1 | RENIN INHIBITORS | REN, ACE, AGT | REN 1/4885CYP3A4 732/4885KCNH2 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.